Rheologics' Demonstrates its Complete Hemorheology Technology Portfolio at the International Congress of Biorheology and the International Conference on Clinical Hemorheology

Single-vendor, dual-technology offering provides measurement and visual clarification to blood movement in capillaries

ANTALYA, Turkey - September 18, 2002 - Rheologics, Inc., a pioneer in the prevention and treatment of heart disease and stroke, today announced that its in-vitro / in vivo blood profiling device, the Rheolog™, and its non-invasive blood vessel imaging technology, the Cytoscan™, will be displayed together for the first time at the 11th International Congress of Biorheology and the 4th International Clinical Conference on Hemorheology, a scientific conference taking place in Antalya, Turkey, September 22 - 26, 2002. Rheologics' medical device technologies provide the medical community with a comprehensive technology platform for studying the dynamics of blood flow and its impact on vascular-related diseases and the development of new cardiovascular drugs. The devices can be deployed by physicians as a system or independently for diagnostic applications including ophthalmic procedures, wound-care, and treatments for diabetes, heart disease and stroke.

"The rheological properties of blood at very low shear rates approaching stasis are of particular interest for hemodynamics in the microcirculation. Unfortunately, the panoply of instrumentation available for the researcher in hemorheology does not derive such viscosity measurements and is too complicated for routine clinical application," said Salvatore P. Sutera, Ph.D., P.E., Washington University. "However, the Rheolog™ scanning capillary viscometer developed by Rheologics, Inc. has been designed from the ground up for the quick and convenient, economical, bedside-friendly assay of the viscosity of whole, unadulterated blood. In a matter of minutes it processes a small sample of blood directly from a venipuncture -- no anticoagulants are necessary -- and delivers a profile of apparent viscosity over a shear-rate range of 1 to 300 inverse seconds."

Rheologics Technology Portfolio
The company's breakthrough product, the Rheolog™, is the industry's first clinically practical device for measuring the biophysical properties of whole human blood within in-vitro laboratory settings and in vivo screening environments at the patient point-of-care. The comprehensive rheological profile produced by the instrument provides biodeliverability effects data that complements product life cycle management strategies, aids in the treatment of heart disease and stroke, and assists with the assessments made during drug screening, compound evaluation and patent extension programs.

The Cytoscan™ complements the Rheolog technology by providing physicians with more diagnostic options. It allows physicians to better monitor perfusion changes in internal organs, allowing them to better observe post-surgical disease states -- ranging from cardiopulmonary bypasses to organ transplants -- without the need for dyes or surgery. The instrumentation is a patented video microscope/ soft-tissue probe that captures still images of illuminated subject matter through a unique backlighting approach. Defined as Orthogonal Polarization Spectral Imaging, the Cytoscan™ technology processes still images according to a proprietary set of algorithms; the differences in the resulting calculations provide a visualization of the subject's cell movements. This technology offers an entry-level blood viscosity (a biophysical property that focuses on a fluid's resistance to flow) measurement. Both devices can be used to monitor patients, thereby becoming an important component of healthcare management for cardiovascular disease.

"Physicians can now look to Rheologics to provide minimally invasive, patient-friendly technology to better manage how a drug is absorbed into the organs and how quickly the body administers it via the bloodstream," said Kenneth R. Kensey, M.D., CEO of Rheologics. "The Rheolog measures the biophysical properties of blood, which affect cardiac output. Whereas the Cytoscan visualizes perfusion, the permeability and diffusion of blood through the capillaries. Perfusion is affected by blood pressure, oxygen, etc., which impacts the cells' ability to absorb blood."

Held every four years, this year's scientific conference in Antalya, Turkey marks the third joint meeting of the International Societies of Biorheology and Clinical Hemorheology, which was first established in 1995 at Big Sky, Montana, U.S.A. and reconvened at Pecs, Hungary in 1999. The 2002 scientific program consists of 23 symposia on the subjects of applied and clinical rheological phenomena. For more information, please visit the website www.akdeniz.edu.tr/icbicch/.

About Rheologics, Inc.
Since 1997, Rheologics has pioneered a new standard of care in the prevention and treatment of heart disease and stroke. Rheologics' mission is to supplement the existing understanding of the risk factors for these diseases by focusing on the emerging field of hemorheology - the study of the dynamics of blood flow and its impact on vascular-related diseases. The company's breakthrough product, the Rheolog™, is the industry's first clinically practical device for measuring the biophysical properties of whole human blood within in-vitro laboratory settings and in vivo screening environments at the patient point-of-care. The comprehensive rheological profile produced by the instrument provides biodeliverability effects data that complements product life cycle management strategies and assists with the assessments made during drug screening, compound evaluation and patent extension programs. Rheologics' portfolio also includes currently available, non-invasive cell imaging technology through the Cytoscan™, a device that enables physicians to better monitor post-surgical disease states. Both instruments will aid in the development of new therapies and diagnostic capabilities for a variety of disease states. The company is headquartered in Exton, Pennsylvania. For more information, please call 1-800-969-2585 or visit the company web site at www.rheologics.com.

¹ Both the Rheolog and the Cytoscan are classified as IDE exempt devices by the FDA guidelines and are not approved by the FDA for therapeutic and diagnostic use. The Cytoscan received a CE mark in December 2000. The Rheolog is currently used by leading institutions for research purposes.

Contacts:
K.C. Du Fay
Sterling Communications
415-749-6550
kcdufay@sterlingpr.com